Open AccessPlasma Angiopoietin 2 Concentrations Are Related to Impaired Lung Function and Organ Failure in a Clinical Cohort Receiving High-Dose Interleukin 2 Therapy
Author(s) -
Kathryn M. Gores,
Angela Delsing,
Sara Kraus,
Linda S. Powers,
Daniel A. Vaena,
Mohammed Milhem,
Martha M. Monick,
Kevin C. Doerschug
Publication year - 2014
Publication title -
shock
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.095
H-Index - 117
eISSN - 1540-0514
pISSN - 1073-2322
DOI - 10.1097/shk.0000000000000188
Subject(s) - medicine , pathophysiology , gastroenterology , sepsis , spirometry , pulmonary function testing , pulmonary edema , lung , endocrinology , asthma
The pathophysiology and therapeutic options in sepsis-induced lung injury remain elusive. High-dose interleukin 2 therapy (HDIL-2) is an important protocol for advanced malignancies but is limited by systemic inflammation and pulmonary edema that is indistinguishable from sepsis. In preclinical models, IL-2 stimulates angiopoietin 2 (AngP-2) secretion, which increases endothelial permeability and causes pulmonary edema. However, these relationships have not been fully elucidated in humans. Furthermore, the relevance of plasma AngP-2 to organ function is not clear. We hypothesized that plasma AngP-2 concentrations increase during HDIL-2 and are relevant to clinical pathophysiology.